Asterion engineers hormone agonists and antagonists to provide therapies for disease states that include cancer, rheumatoid arthritis and diabetes. Currently available therapies based upon recombinant protein drugs can exhibit rapid clearance and degradation, a commercial and practical disadvantage meaning that patients usually require daily injections with associated high production costs.

Asterion's intellectual property portfolio enables the design and generation of recombinant protein pharmaceuticals that will be facing patent expiry.

The technology platform to generate growth hormone agonists and antagonists is being developed with a major pharmaceutical company and